Latent Toxoplasmosis in Females With Borderline Personality Disorder

April 1, 2024 updated by: Marie Ociskova

Latent Toxoplasmosis in Females With Borderline Personality Disorder - Occurrence, Clinical Features, and Impact on Effectiveness of Combined Pharmacotherapeutic and Psychotherapeutic Treatment

Borderline personality disorder is a common mental disorder with core features of affective dysregulation, impulsivity, and identity disturbance. Although this disorder is mostly understood as a result of a combination of biological factors (genes, temperament) and early aversive experiences (often of traumatic nature), recent data suggest that other factors may be important in its development and course. Preliminary findings show that patients with borderline personality disorder have higher prevalence of Toxoplasma seropositivity. This infection may manifest in symptoms such as affective dysregulation, aggression, suicidality, or anxiousness. As such, it may play a role in the psychopathology of the borderline personality disorder. The aim of this study is to explore the prevalence of Toxoplasma seropositivity in a sample of females with borderline personality disorder, its clinical correlates, and a potential impact on outcomes of an intensive six-week inpatient schema-therapeutic treatment. Results may enrich our understanding of this disorder and lead to improvements of the therapeutic approaches.

Study Overview

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Olomouc, Czechia, 77900
        • Department of Psychiatry, Palacky University, University Hospital Olomouc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Female patients with borderline personality disorder who will be hospitalized at the psychotherapeutic ward of the university hospital.

Description

Inclusion Criteria:

  • Adult
  • Female
  • Borderline personality disorder diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders-5 criteria
  • Signed informed consent

Exclusion Criteria:

  • Current substance abuse disorder
  • Psychotic disorder, bipolar disorder, organic mental disorder current or past
  • Severe suicidal risk
  • Severe somatic illness (e.g., endocrinopathy, oncologic, hematologic, cardiologic, or neurologic illness)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Females with borderline personality disorder
A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunoglobulin A detection in human serum
Time Frame: 1 day
ELISA detection of immunoglobulin A specific antibodies - a sensitive and specific marker of acute infection. Index of positivity is higher than 1,1.
1 day
Immunoglobulin M detection in human serum
Time Frame: 1 day
ELISA detection of immunoglobulin M specific antibodies - a highly sensitive marker of acute infection. Index of positivity is higher than 1,1.
1 day
Immunoglobulin G detection in human serum
Time Frame: 1 day
ELISA detection of immunoglobulin G specific antibodies - a marker of undergone infection. The cut-off score for positivity is set at higher than 6,6 IU/ml.
1 day
Severity of borderline personality symptoms
Time Frame: 1 year
Assessed by modified Clinical Global Impression for borderline personality disorder which was developed by Pérez et al (2007). This rating scale measures severity of the nine diagnostic criteria of the disorder, along with its overall severity. In each item, a clinician chooses one number of a seven-point scale where 1 = normal, not at all ill and 7 = among the most extremely ill subjects. The scores in the items are not summed. Instead, each of the item enters statistical analyses separately.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Borderline Evaluation of Severity over Time
Time Frame: 1 year
This self-rating scale evaluates common symptoms of borderline personality disorder during a specified time range (7 days, 30 days, or other) (Pfohl et al. 2009). 15 items divide into three subscales - thoughts and feelings, behaviors (negative), and behaviors (positive). The patient responds to each item on a 5-point scale according to how much the symptom caused her distress, relationship issues, or disability (in the thoughts and feelings and negative behaviors subscales) and how often she engaged in positive behaviors. The total score ranges between 12 and 72, with higher scores indicating more severe symptomatology.
1 year
Aggression Questionnaire
Time Frame: 1 year
The questionnaire, created by Buss and Perry (1992), has 29 items that are divided into four factors - physical aggression, verbal aggression, anger, and hostility. The patient chooses a number from a five-point scale according to how much is each statement characteristic of her. The total score varies from 29 to 145; higher scores indicating more pronounced aggressive tendencies.
1 year
Suicide Behaviors Questionnaire-Revised
Time Frame: 1 year
The questionnaire has four items that evaluate suicidality - a lifetime frequency of suicide ideation and/or attempt, a frequency of suicidal ideation in the last 12 months, a frequency of threats of suicide attempt, and self-reported likelihood of suicidal behavior in the future (Osman et al. 1999). The total score ranges from 3 to 18; higher scores indicate more severe suicidality.
1 year
Beck Anxiety Inventory
Time Frame: 1 year
The self-rating inventory measures 21 symptoms of anxiety in the time span of a week (Beck et al. 1988). The patient evaluates each symptom with a four-point scale where higher scores mean more severe symptomatology. The total score varies from 0 to 63 points.
1 year
Beck Depression Inventory-II
Time Frame: 1 year
The self-rating inventory measures 21 symptoms of depression during the last two weeks (Beck et al. 1996). The patient chooses perceived severity of each symptom. The total score can reach 0 to 63 points, higher scores representing more severe depressive symptomatology.
1 year
Dissociative Experiences Scale
Time Frame: 1 year
The scale focuses on 28 dissociative symptoms that include dissociative amnesia, depersonalization, derealization, and absorption (Bernstein and Putnam 1986). The patient marks a spot on a 10-cm scale according to how often she perceives the symptom. The total score ranges from 0 to 100 - this number denotes how much time the individual spends in dissociative states.
1 year
Sheehan Disability Scale
Time Frame: 1 year
The scale assesses the level of functional impairment in three areas - work/school, social, and family life (Sheehan 1983). The patient chooses a number from 0 to 10 according to how much her mental disorder disrupted her functioning in each area. The total score then ranges from 0 to 30, higher scores meaning larger disability.
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Childhood Trauma Questionnaire
Time Frame: 1 day
The questionnaire was created by Bernstein et al. (1994) as a screening for history of child abuse and neglect. It consists of 28 items divided into five factors - emotional, sexual, and physical abuse and emotional and physical neglect. In each item, the patient states how often she experienced described situation on a five-point scale (1 = never, 5 = very often). A total score of each subscale is then calculated; higher scores mean more aversive experiences in childhood.
1 day
Parental Bonding Instrument Questionnaire
Time Frame: 1 day
The questionnaire retrospectively evaluates parental attachment (separately for each parent) up to 16 years of age (Parker 1979). It consists of 25 items divided into two subscales - care and overprotection. The patients evaluates each item on a four-point scale according to how much she finds the statement fitting to her parents. The results are separate for the parents. Each of them get two scores - one for care and one for overprotection. The lowest score of the subscales is 0, the highest is 36 (for the care subscale) or 39 points (for the overprotection subscale). The parental bonding then may be assigned into four categories - affectionate constraint, affectionless control, optimal parenting, and neglectful parenting.
1 day
Internalized Stigma of Mental Illness Scale
Time Frame: 1 day
The scale was developed by Ritsher et al. (2003). In 29 items, it measures the extent of internalized stigma (in other words self-stigma). The scale consists of five subscales - alienation, stereotype endorsement, perceived discrimination, social withdrawal, and stigma resistance. Each statement is rated with a four-point scale according to how much the patient agrees with it. The total score lies between 29 and 116 points, higher score indicating more severe self-stigma.
1 day
The Experiences in Close Relationship-Revised Questionnaire
Time Frame: 1 day
The questionnaire evaluates two basic dimensions of adult attachment - attachment-related anxiety and attachment-related avoidance (Fraley et al. 2000). The measurement consists of 36 items, first half assessing the anxiety, the second half evaluating the avoidance. Each item is rated on a seven-point scale according to the level of agreement. There are two resultant scores (one for the anxiety subscale, the other for the avoidance subscale) which present the means of the items in each subscale. These scores can lie between 1 and 7, higher scores indicating more intensive attachment-related anxiety and attachment. By a comparison with norms, it is possible to define four attachment types - secure, dismissing, fearful, and preoccupied.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Marie Ociskova, PhD, University Hospital Olomouc, Faculty of Medicine, Palacky University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

November 1, 2023

Study Completion (Actual)

April 1, 2024

Study Registration Dates

First Submitted

April 22, 2019

First Submitted That Met QC Criteria

April 26, 2019

First Posted (Actual)

May 1, 2019

Study Record Updates

Last Update Posted (Actual)

April 2, 2024

Last Update Submitted That Met QC Criteria

April 1, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe